Figures
- FIGURE 1
Pre-treatment a) chest radiograph, showing infiltration shadows in the upper right lobe and miliary shadows in both lungs; and b) CT scan, showing diffuse miliary shadows in both lungs.
- FIGURE 2
Clinical course of the mother in our hospital. Day 1 was the day of admission. The mother's general condition improved at discharge as a result of continued administration of anti-tuberculosis drugs and methylprednisolone. C-reactive protein (CRP) decreased and albumin recovered. Drug eruptions appeared twice, both of which were caused by antibiotics.
- FIGURE 3
Changes in chest radiographs. a) At the time of admission (on the first day, before delivery) the miliary shadow in both lungs and infiltration shadow in the right upper lobe are seen. b) On the third day after admission (following delivery), the infiltration shadow spread to both lungs, indicating ARDS. c) On the 15th day, at the time of withdrawal from the ventilator, the miliary and infiltration shadows in both lungs improved; and d) on the 21st day (discharge from our hospital), the infiltration shadow improved further, mainly in the left lung.
- FIGURE 4
a) Erythema on the upper right arm. b) Erythema expanding on the right arm, with no rash noted on other parts of the body.
- FIGURE 5
Changes in computed tomography findings. a) Miliary tuberculosis observed in both lungs at the time of admission. b) Persistence of infiltration shadow due to pneumonia developed during hospitalisation, noted before discharge from our hospital. c) Improved miliary and infiltration shadows compared to previous images.
Tables
- TABLE 1
Blood analyses
Parameter Value Normal range Haematocrit, % 32.2 35–45 Haemoglobin, g·dL−1 10.1 11.8–15.1 White blood cells, ×109 per L 7.4 4.0–9.6 Neutrophils, % 91.8 42.2–73.2 Eosinophils, % 0.5 0.5–7.3 Basophils, % 0.1 0.0–1.8 Monocytes, % 2.2 2.2–8.4 Lymphocytes, % 5.4 20.1–47.3 Platelets, ×109 per L 275 160–350 Fibrinogen, mg·dL−1 435 150–330 Prothrombin time/international normalised ratio 0.97 0.85–1.23 Fibrin/fibrinogen degradation products, µg·mL−1 19.4 0.0–4.0 D-dimer, µg·mL−1 8.9 0.0–1.0 Total protein, g·dL−1 4.7 6.3–7.9 Serum albumin, g·dL−1 1.7 3.9–5.0 Immunoglobulin G, mg·dL−1 648 870–1700 Total bilirubin, mg·dL−1 0.6 0.3–1.2 Alanine transaminase, U·L−1 11 6–27 Aspartate transaminase, U·L−1 22 13–33 Alkaline phosphatase, U·L−1 213 38–113 Lactate dehydrogenase, U·L−1 325 124–222 Creatine kinase, U·L−1 32 45–163 Amylase, U·L−1 34 37–125 Serum sodium, mEq·L−1 132 136–147 Serum potassium, mEq·L−1 3.6 3.6–5.0 Serum chloride, mEq·L−1 100 98–109 Blood urea nitrogen, mg·dL−1 4 8–20 Creatinine, mg·dL−1 0.45 0.46–0.79 Brain natriuretic peptide, pg·mL−1 4.3 ≤18.4 C-reactive protein, mg·dL−1 10.46 ≤0.14 Sialylated carbohydrate antigen KL-6, U·mL−1 838 <500 β-D-glucan, pg·dL−1 <2.6 ≤20 Aspergillus antigen Negative Negative Mycoplasma pneumoniae antibody <40-fold <40-fold Cytomegalovirus antigenaemia test Negative Negative Hepatitis B surface antibody Negative Negative Hepatitis C antibody Negative Negative HIV antibody Negative Negative COVID-19 antigen test Negative Negative COVID-19 antibody test Negative Negative T-SPOT.TB test Positive Negative Arterial blood gas analysis# pH 7.354 PaO2, mmHg 116 PaCO2, mmHg 39.8 Base excess, mEq·L−1 −3.0 PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension. #: with oxygen 5 L·min−1 by face mask.
